Danske Bank’s Oruka Therapeutics ORKA Stock Holding History

Danske Bank’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$49	–	1680
2024 Q3	$49	Buy	+2	New	+$70	﹤0.01%	1475

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Danske Bank's ORKA Position: Q4 2024 in Review

Danske Bank sold out of Oruka Therapeutics (ORKA) in Q4 2024, closing a stake of 2 shares — an estimated $49 sold.

Danske Bank first reported a position in ORKA in Q3 2024 and held it in 1 quarter. The position peaked at $49 in Q3 2024. 66 funds tracked by Wall St. Rank hold ORKA as of Q4 2024.

Danske Bank reported no remaining Oruka Therapeutics position as of Q4 2024 after selling out during the quarter.
Danske Bank sold 2 Oruka Therapeutics shares in Q4 2024, an estimated $49.
Danske Bank first reported a position in Oruka Therapeutics in Q3 2024 and held it in 1 quarter.
Danske Bank's Oruka Therapeutics position peaked at $49 in Q3 2024.
66 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.